OPK vs. INVA, IRWD, MNKD, LXRX, PCRX, DVAX, ADCT, VSTM, AVIR, and VNDA
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), Pacira BioSciences (PCRX), Dynavax Technologies (DVAX), ADC Therapeutics (ADCT), Verastem (VSTM), Atea Pharmaceuticals (AVIR), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.
64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 47.3% of OPKO Health shares are owned by company insiders. Comparatively, 1.4% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, OPKO Health had 3 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for OPKO Health and 5 mentions for Innoviva. Innoviva's average media sentiment score of 1.75 beat OPKO Health's score of 1.34 indicating that Innoviva is being referred to more favorably in the news media.
Innoviva has a net margin of 58.21% compared to OPKO Health's net margin of -31.44%. Innoviva's return on equity of 28.94% beat OPKO Health's return on equity.
OPKO Health currently has a consensus target price of $3.17, indicating a potential upside of 132.84%. Given OPKO Health's higher probable upside, equities analysts clearly believe OPKO Health is more favorable than Innoviva.
OPKO Health has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
OPKO Health received 203 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.70% of users gave OPKO Health an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Summary
Innoviva beats OPKO Health on 9 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
